@article{292b618af0f84b44bb8fed9bc66ab082,
title = "Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong",
abstract = "Background and objective: Few head-to-head evaluations of immune responses to different vaccines have been reported. Methods: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or CoronaVac (n = 360) vaccines in Hong Kong were determined. An age-matched subgroup (BNT162b2 [n = 49] vs. CoronaVac [n = 49]) was tested for plaque reduction neutralization (PRNT) and spike-binding antibody and T-cell reactivity in peripheral blood mononuclear cells. Results: One month after the second dose of vaccine, BNT162b2 elicited significantly higher PRNT50, PRNT90, sVNT, spike receptor binding, spike N-terminal domain binding, spike S2 domain binding, spike FcR binding and antibody avidity levels than CoronaVac. The geometric mean PRNT50 titres in those vaccinated with BNT162b2 and CoronaVac vaccines were 251.6 and 69.45, while PRNT90 titres were 98.91 and 16.57, respectively. All of those vaccinated with BNT162b2 and 45 (91.8%) of 49 vaccinated with CoronaVac achieved the 50% protection threshold for PRNT90. Allowing for an expected seven-fold waning of antibody titres over 6 months for those receiving CoronaVac, only 16.3% would meet the 50% protection threshold versus 79.6% of BNT162b2 vaccinees. Age was negatively correlated with PRNT90 antibody titres. Both vaccines induced SARS-CoV-2-specific CD4+ and CD8+ T-cell responses at 1 month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4+ and CD8+ T-cell responses. Conclusion: Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induces higher CD4+ and CD8+ T-cell responses to the structural protein than BNT162b2.",
keywords = "Biontech, BNT162b2, CoronaVac, coronavirus disease, COVID-19, immunogenicity, SARS-CoV-2, Sinovac",
author = "Mok, {Chris Ka Pun} and Cohen, {Carolyn A.} and Cheng, {Samuel M.S.} and Chunke Chen and Kwok, {Kin On} and Karen Yiu and Chan, {Tat On} and Maireid Bull and Ling, {Kwun Cheung} and Zixi Dai and Ng, {Susanna S.} and Lui, {Grace Chung Yan} and Chao Wu and Amarasinghe, {Gaya K.} and Leung, {Daisy W.} and Wong, {Samuel Yeung Shan} and Valkenburg, {Sophie A.} and Malik Peiris and Hui, {David S.}",
note = "Funding Information: The study was partly supported by Fast Grant ##2161 (Emergent Ventures to Gaya K. Amerasinghe) and NIH grants (P01AI120943 and R01AI123926 to Gaya K. Amerasinghe; R01AI107056 to Daisy W. Leung). Funding Information: Fast Grant, Grant/Award Number: 2161; National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme, Grant/Award Numbers: T11‐705/21‐N, T11‐712/19‐N, N_HKU737/18; US National Institutes of Health, Grant/Award Numbers: R01AI107056, R01AI123926, P01AI120943, HHSN272201400006C; National Research Foundation of Korea (NRF), Grant/Award Number: NRF‐2018M3A9H4055203; Guangdong Province International Scientific and Technological Cooperation Projects, Grant/Award Number: 2020A0505100063; Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID‐19), Hong Kong SAR, Grant/Award Numbers: COVID‐190126, COVID‐190115, COVID1903003; Pasteur Foundation Asia Funding information Funding Information: We acknowledge the technical support from Mr Huibin Lv and Mr Ho Lun Lai. We also thank Dr Fung Hong (Chinese University Medical Center), Dr Ken Tsang (Kowloon Bay community vaccination centre) and Dr Beatrice Cheng (Prince of Wales Hospital) for allowing us to recruit subjects for this study. The recombinant RBD and NTD proteins were kindly gifted by Prof Ian A. Wilson and Dr Meng Yuan. This project utilized an Invitrogen Attune flow cytometer funded by the Pasteur Foundation Asia which is a non-profit organization. Research funding: This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003) (Chris Ka Pun Mok, Susanna S. Ng, Grace Chung-Yan Lui, Malik Peiris and David S. Hui) (COVID-190115 and?COVID-190126, Sophie A. Valkenburg); Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (Chris Ka Pun Mok); the National Research Foundation of Korea (NRF) grant funded through the Korea Government (NRF-2018M3A9H4055203) (Chris Ka Pun Mok); US National Institutes of Health (contract no. HHSN272201400006C) (Malik Peiris); National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (Chris Ka Pun Mok and Malik Peiris); and RGC theme-based research scheme (T11-712/19-N and T11-705/21-N) (David S Hui). The research was partly supported by Fast Grant ##2161 (Emergent Ventures to Gaya K. Amerasinghe) and NIH grants (P01AI120943 and R01AI123926 to Gaya K. Amerasinghe; R01AI107056 to Daisy W. Leung). The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Funding Information: We acknowledge the technical support from Mr Huibin Lv and Mr Ho Lun Lai. We also thank Dr Fung Hong (Chinese University Medical Center), Dr Ken Tsang (Kowloon Bay community vaccination centre) and Dr Beatrice Cheng (Prince of Wales Hospital) for allowing us to recruit subjects for this study. The recombinant RBD and NTD proteins were kindly gifted by Prof Ian A. Wilson and Dr Meng Yuan. This project utilized an Invitrogen Attune flow cytometer funded by the Pasteur Foundation Asia which is a non‐profit organization. Funding Information: : This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID‐19), Hong Kong SAR (COVID1903003) (Chris Ka Pun Mok, Susanna S. Ng, Grace Chung‐Yan Lui, Malik Peiris and David S. Hui) (COVID‐190115 and COVID‐190126, Sophie A. Valkenburg); Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (Chris Ka Pun Mok); the National Research Foundation of Korea (NRF) grant funded through the Korea Government (NRF‐2018M3A9H4055203) (Chris Ka Pun Mok); US National Institutes of Health (contract no. HHSN272201400006C) (Malik Peiris); National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (Chris Ka Pun Mok and Malik Peiris); and RGC theme‐based research scheme (T11‐712/19‐N and T11‐705/21‐N) (David S Hui). The research was partly supported by Fast Grant ##2161 (Emergent Ventures to Gaya K. Amerasinghe) and NIH grants (P01AI120943 and R01AI123926 to Gaya K. Amerasinghe; R01AI107056 to Daisy W. Leung). The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Research funding Publisher Copyright: {\textcopyright} 2021 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.",
year = "2022",
month = apr,
doi = "10.1111/resp.14191",
language = "English",
volume = "27",
pages = "301--310",
journal = "Respirology",
issn = "1323-7799",
number = "4",
}